Also, during the first quarter, and under the direction of Arbutus’ Chief Scientific Officer, Dr. Michael Sofia, the Company has initiated an internal research program to identify new small molecule antiviral medicines to treat COVID-19 and future CORONAVIRUS outbreaks. Dr. Sofia, who was awarded the Lasker-DeBakey Award for his discovery of sofosbuvir, brings extensive antiviral drug discovery experience to this new program. Arbutus has also joined forces with the COVID R&D CONSORTIUM to further support and expedite efforts to address the COVID-19 pandemic.
The establishment of the COVID-19 effort does not impact Arbutus’ current cash burn guidance for 2020 of $54 to $58 million.
also, meine vermutungen werden bestätigt.
abus forscht auch im CORONAvirussektor und
ist mitglied im (vermutl. kanadischem) KONSORTIUM ( = stattl. forschungsgeld ? ),
was keiner großen zusätzlichen investitionen bedarf.